Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A novel therapeutic strategy against monocytic leukemia with deoxyadenosine analogs and adenosine deaminase inhibitors
Autore:
Honma, Y;
Indirizzi:
Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan Saitama Canc Ctr Ina Saitama Japan 3620806 t, Ina, Saitama 3620806, Japan
Titolo Testata:
LEUKEMIA & LYMPHOMA
fascicolo: 5, volume: 42, anno: 2001,
pagine: 953 - 962
SICI:
1042-8194(200109/10)42:5<953:ANTSAM>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; HAIRY-CELL LEUKEMIA; CYTOCHROME-C; 2ND MALIGNANCIES; DEPENDENT ACTIVATION; CASPASE-9 ACTIVATION; RANDOMIZED TRIAL; KAPPA-B; ARA-A;
Keywords:
monocytic leukemia; adenosine deaminase inhibitor; deoxyadenosine analogs; apoptosis; differentiation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
75
Recensione:
Indirizzi per estratti:
Indirizzo: Honma, Y Saitama Canc Ctr, Res Inst, 818 Komuro, Ina, Saitama 3620806, Japan Saitama Canc Ctr 818 Komuro Ina Saitama Japan 3620806 0806, Japan
Citazione:
Y. Honma, "A novel therapeutic strategy against monocytic leukemia with deoxyadenosine analogs and adenosine deaminase inhibitors", LEUK LYMPH, 42(5), 2001, pp. 953-962

Abstract

The adenosine deaminase inhibitor 2'-deoxycoformycin (dCF) significantly inhibits the proliferation of leukemia and lymphoma cells in the presence ofeither 2'-deoxyadenosine (dAdo) or its analog adenine arabinoside (araA). The concentration of dCF required to induce apoptosis of monocytoid leukemia cells is much lower than that required for myeloid, erythroid, or lymphoma cells. dATP effectively induces caspase-3 activation in cytosol from monocytoid cells, but not in that from non-monocytoid cells, suggesting that dATP-dependent caspase-3 activation is involved in the preferential inductionof apoptosis in monocytoid leukemia cells. Athymic nude mice inoculated with human monocytoid leukemia U937 cells show significantly prolonged survival following combined treatment with dCF and araA- The clinical usefulness of the combination of adenosine deaminase inhibitor and dAdo analog is discussed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/09/20 alle ore 15:20:31